Part the Cloud Translational (PTC) Research for Alzheimer’s Disease Program: Phase 1 and Phase 2 Clinical Studies
Part the Cloud Translational (PTC) Research supports academic investigators and small companies in early human studies of Alzheimer’s therapies to establish safety and proof of mechanism before larger trials.
Funder: Alzheimer's Association
Due Dates: October 20, 2026 (LOI) | October 22, 2026 (ISTAART LOI) | December 15, 2026 (Full application) | December 17, 2026 (ISTAART full application); all at 5 p.m. ET
Funding Amounts: Up to $1,000,000 total for two to three years
Summary: Supports early-stage human clinical studies of novel or repurposed therapies for Alzheimer’s disease and related dementias internationally.
Key Information: Applicants must hold a full-time Assistant Professor–equivalent position or higher; an approved current-cycle LOI is required.
Description
The Alzheimer’s Association’s Part the Cloud Translational Research program addresses the funding gap between preclinical therapeutic development and early human testing. It supports academic investigators and small companies internationally, with a focus on Phase 1 and pilot Phase 2 studies that establish safety, brain penetration, target engagement, or proof of mechanism before larger efficacy trials.
Eligible work includes lead candidates entering Phase 1, therapies with established human safety data needing pilot proof-of-mechanism studies, and repurposed drugs tested in normal individuals or people with symptomatic or asymptomatic Alzheimer’s disease and related dementias. Proof-of-concept studies validating biomarkers of disease progression in clinical trials are also supported. Some Phase 3 studies may qualify depending on scope and scale. All projects must be translational and clearly focused on Alzheimer’s disease and related disorders.
